Finding advances search for cure other than liver transplantation
A protein modified to increase the amount of time it circulates in the bloodstream appears to reverse liver fibrosis and cirrhosis in rats, according to results of a study led by Johns Hopkins researchers.
The investigators say the findings, reported ahead of print in the March 3 early view edition of Hepatology, advance the search for a potential cure for the thousands of patients worldwide living with these incurable diseases. At present, there is little effective treatment and no cure other than liver transplantation, which carries its own risks and often fails.
“Our findings demonstrate that the damaging effects of liver cirrhosis in laboratory rats can be effectively treated, and perhaps even reversed, using a protein therapeutic that has been modified to enhance its activity through site-specific conjugation of a polymer that greatly enhances its residence time in the body,” says senior author Justin Hanes, Ph.D., director of the Center for Nanomedicine at the Wilmer Eye Institute at Johns Hopkins. “This approach has tremendous potential to help people with this devastating condition and may also be helpful to the millions of patients with other diseases where fibrosis plays an important role.”
Liver fibrosis and its more severe form, cirrhosis, are caused by scar tissue that forms in the liver that is usually induced by chronic alcohol abuse, infections and autoimmune diseases. The progressive stiffening of the liver, a hallmark of the disorders, occurs when a type of liver cell known as the hepatic stellate cell is “activated” and overproduces the stringy network of proteins called the extracellular matrix that binds cells together.
Being able to turn cirrhosis around, especially in its late stages, would be a great boon, says Seulki Lee, Ph.D., assistant professor in the Department of Radiology and Radiological Science at the Johns Hopkins University School of Medicine. “That’s because liver fibrosis and cirrhosis can be asymptomatic for decades,” Lee says. “Many patients only seek treatment when their disease becomes very advanced, at which point liver transplant is their only option.”
Lee cautions, however, that his team’s work is years from any possible application to patients.
Scientists have known for more than a decade that a protein called tumor necrosis factor-related apoptosis-inducing ligand — TRAIL, for short — can specifically kill activated hepatic stellate cells that overproduce the extracellular matrix, sparing healthy cells in the liver. However, Lee explains, TRAIL has thus far proven unsuccessful for clinical use because in animal studies, enzymes in the bloodstream quickly degrade it before it has time to work.
Seeking a way to extend TRAIL’s half-life, or the time that it remains intact in the bloodstream, Lee and his colleagues coated TRAIL with polyethylene glycol (PEG), a synthetic polymer that’s widely used as a preservative, lubricant and ingredient in skin creams, and is already being used to extend the bloodstream life of a handful of drugs that treat neutropenia, hemophilia and rheumatoid arthritis.
Lee says initial experiments showed that this “PEGylated” TRAIL had a half-life of between eight and nine hours in monkeys, compared to less than 30 minutes for the unmodified protein. When the scientists intravenously dosed rats that had liver fibrosis with the modified TRAIL for 10 days, the animals’ activated hepatic stellate cells died off. By fighting these bad cells, signs of fibrosis began to diminish. Further investigation showed that multiple genes associated with fibrosis had reduced activity, and the proteins produced by these genes faded away.
Findings were similar in rats with advanced cirrhosis, Lee says. Additionally, when the researchers examined the rodents’ liver tissue under a microscope, they found that animals treated with PEGylated TRAIL had fewer deposits of collagen and other extracellular matrix proteins, offering some evidence that the disease had actually been reversed.
Further experiments showed that PEGylated TRAIL selectively killed human-activated hepatic stellate cells growing in petri dishes while leaving normal liver cells unharmed, suggesting that findings in these animal models could apply to damaged human livers with limited toxicity concerns.
Lee says the research team hopes to develop PEGylated TRAIL for clinical trials in human patients in the next two years. He adds that some preliminary data suggest that the modified protein could also treat other fibrotic diseases as well, such as pancreatic or lung fibrosis, which also have no effective treatment.
“Eventually,” Lee says, “we might be able to develop PEGylated TRAIL into a universal anti-fibrotic agent that can treat many different conditions.”
Learn more: Modified protein reverses cirrhosis in lab rats
The Latest on: Protein therapeutic
via Google News
The Latest on: Protein therapeutic
- Targeted deletion of NFAT-Interacting-Protein-(NIP) 45 resolves experimental asthma by inhibiting Innate Lymphoid Cells group 2 (ILC2)on October 30, 2019 at 4:49 am
Here we investigated the role of NFAT-interacting protein (NIP)-45, an Interleukin (IL)-4 inducing Transcription Factor ... ILC2 markers in ILC2 differentiated from the bone marrow of NIP45 −/− mice.
- Beactica Therapeutics Participates in Innovative Training Network on Targeted Protein Degradationon October 30, 2019 at 12:23 am
Beactica Therapeutics Participates in Innovative Training Network on Targeted Protein Degradation PR Newswire UPPSALA, Sweden, Oct. 30, 2019 UPPSALA, Sweden, Oct. 30, 2019 /PRNewswire/ -- Beactica ...
- Telix Pharmaceuticals and AusHealth to Partner on Novel Therapeutics for Lung, Ovarian Canceron October 29, 2019 at 5:23 pm
The APOMAB technology uses antibodies to deliver radiation to cancer cells that express the La/SSB protein, which is present on the surface of certain types ... Telix CEO Dr. Christian Behrenbruch ...
- Here's Why Mirati Therapeutics Stock Is on the Move Again Todayon October 29, 2019 at 2:02 pm
Unfortunately, KRAS proteins have a relatively smooth shape that has made them impossible to inhibit ... and perhaps 4% of colon cancer patients have tumors driven by the KRAS mutation that MRTX849 ...
- Bio-Techne investing up to $50M in new plant for recombinant proteinson October 29, 2019 at 7:50 am
"As the promising science behind emerging cell and gene therapy applications continues to demonstrate therapeutic effectiveness, the focus must now be on supply and scale,” Dave Eansor, Bio-Techne's ...
- Allogene Therapeutics: Stay On The Sidelines On This Until 2020on October 29, 2019 at 5:50 am
Allogene Therapeutics has raised close to US$800M in funds since April 2018 and assembled ... Their most advanced product candidates, UCART19 and ALLO-501, both target CD19, which is a protein ...
- Pro-inflammatory protein could play key role in protecting against herpes viruson October 29, 2019 at 4:59 am
Researchers at the University of Arizona College of Medicine - Phoenix have discovered a function in a pro-inflammatory protein that could play an important part in improving current and future ...
- Study finds inflammatory protein can protect against spread of herpes viruson October 28, 2019 at 8:52 am
Researchers at the University of Arizona College of Medicine—Phoenix have discovered a function in a pro-inflammatory protein that could play an important part in improving current and future ...
- Microprotein Could Point to New Therapeutic Targets for Diverse Human Diseaseson October 28, 2019 at 6:11 am
Human proteins are typically about 300 amino acids in length ... The findings may help scientists to develop new therapeutic approaches that can target cell stress. “Given the importance of UPR in ...
- Engineered amphiphilic peptides enable delivery of proteins and CRISPR-associated nucleases to airway epitheliaon October 28, 2019 at 3:11 am
Among cargoes, recombinant proteins offer therapeutic promise but the lack of effective delivery methods limits their development. Here, we achieve protein and SpCas9 or AsCas12a ribonucleoprotein ...
via Bing News